{
    "clinical_study": {
        "@rank": "161322", 
        "arm_group": [
            {
                "arm_group_label": "Placebo followed by V158866", 
                "arm_group_type": "Experimental", 
                "description": "Placebo once per day for 4 weeks followed by V158866 450mg once per day for 4 weeks"
            }, 
            {
                "arm_group_label": "V158866 followed by Placebo", 
                "arm_group_type": "Experimental", 
                "description": "V158866 450mg once per day for 4 Weeks followed by Placebo once per day for 4 Weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate whether V158866 is safe and effective for the\n      treatment of neuropathic pain due to spinal cord injury."
        }, 
        "brief_title": "A Safety, Tolerability and Efficacy Study of V158866 in Central Neuropathic Pain Following Spinal Cord Injury", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Neuropathic Pain Due to Spinal Cord Injury", 
        "condition_browse": {
            "mesh_term": [
                "Neuralgia", 
                "Spinal Cord Injuries", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  aged 18 - 65 years\n\n          -  documented spinal cord injury at or below T5\n\n          -  moderate pain at or below the level of the spinal cord injury for at least 3 months\n\n          -  compliant with daily diary\n\n          -  stable pain scores on the NRS\n\n          -  mean pain intensity of at least 4 and not more than 9 on the NRS (or if the mean NRS\n             score is >9, the mean Gracely score must be \u226419)\n\n        Exclusion Criteria:\n\n          -  women of child-bearing potential\n\n          -  men who intend to father a child\n\n          -  a history of multiple drug allergies, hypersensitivity to any cannabinoid\n\n          -  an increased risk of seizure\n\n          -  evidence of depression and/or a score of >19 on the BDI-II\n\n          -  suicidal ideation or suicidal behavior in the past 10 years\n\n          -  a history of substance abuse or dependence within the past year, excluding nicotine\n             and caffeine\n\n          -  a positive urine test for cannabis at screening\n\n          -  taking excluded medications that cannot be stopped\n\n          -  a positive pregnancy test"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01748695", 
            "org_study_id": "V158866-2Pa-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Placebo followed by V158866", 
                    "V158866 followed by Placebo"
                ], 
                "intervention_name": "V158866", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Placebo followed by V158866", 
                    "V158866 followed by Placebo"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Neuropathic pain", 
            "Spinal cord injury"
        ], 
        "lastchanged_date": "January 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02115"
                }, 
                "name": "Brigham and Women's Hospital"
            }, 
            "investigator": {
                "last_name": "Christine N Sang, MD, MPH", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase IIa, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over Study Evaluating the Safety, Tolerability and Efficacy of V158866 in Central Neuropathic Pain Following Spinal Cord Injury", 
        "overall_contact": {
            "email": "csang@partners.org", 
            "last_name": "Christine N Sang, MD, MPH"
        }, 
        "overall_contact_backup": {
            "email": "paintrials@partners.org", 
            "last_name": "Kierin O'Donnell"
        }, 
        "overall_official": {
            "affiliation": "Brigham and Women's Hospital", 
            "last_name": "Christine N Sang, MD, MPH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The primary efficacy endpoint will be the comparison of the overall pain intensity on the NRS for the last 7 days of each treatment period. (V158866 compared to placebo)", 
                "measure": "Change from baseline in mean pain intensity scores on the NRS.", 
                "safety_issue": "No", 
                "time_frame": "4 Weeks"
            }, 
            {
                "description": "Safety and tolerability measured by:\nAdverse events, Columbia Suicide Severity Rating Scale change from baseline, Vital signs change from baseline, 12-lead ECG change from baseline, Beck Depression Inventory change from baseline, Laboratory safety tests changes from baseline, ARC Inventory - marijuana change from baseline, RBANS change from baseline", 
                "measure": "Safety and tolerability of V158866 compared to placebo", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01748695"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Brigham and Women's Hospital", 
            "investigator_full_name": "Christine N. Sang, MD, MPH", 
            "investigator_title": "Dr Christine Sang", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Gracely pain scores will be compared between V158866 and placebo treatment.", 
                "measure": "Gracely pain scores", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Sleep interference scores will be compared between treatment with V158866 and placebo.", 
                "measure": "Sleep interference", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Quantitative Sensory Testing parameters will be compared between treatment with V158866 and placebo", 
                "measure": "Quantitative Sensory Testing", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Brigham and Women's Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Vernalis (R&D) Ltd", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Brigham and Women's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}